Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical
aesthetic and therapeutic skin-health systems, and Suneva Medical, Inc.,
a rapidly growing aesthetics company, jointly announce a partnership to
Facial Rejuvenation Complex.
This technologically advanced product supports a more rapid improvement
in the appearance of post-laser skin by fusing the promise of stem cells
with the power of growth factors. It has been clinically proven to
accelerate the return of healthy appearing skin after a combination
ablative/nonablative laser treatment compared to a vehicle control in
two separate studies published in peer-reviewed journals1,2.
Obagi is extremely pleased to be co-distributing the ReGenica Facial
Rejuvenation Complex, along with the Suneva sales force. It can now
offer a clinically proven post-procedure solution to its physicians and
ReGenica's secret lies in its Multipotent CCM Complex (Cell Conditioned
Media) developed by Dr. Gail K. Naughton, a renowned pioneer in the
field of regenerative medicine. CCM is a highly potent composition of
active growth factors and proteins not found in any other skincare
product and developed through a revolutionary and highly proprietary
scientific method. Only ReGenica contains this breakthrough, bovine
serum-free, multipotent CCM in an innovative formulation optimized with
the most advanced cosmeceutical skin conditioning agents.
"Obagi is delighted to offer another revolutionary skincare solution to
patients. The addition of the ReGenica line solidifies already existing
evidence that Obagi is dedicated to delivering the most efficacious,
innovative products to patients seeking real solutions," Al Hummel,
Obagi's President and CEO, said. "The Facial Rejuvenation Complex
addresses the need for post-procedure skincare treatments that are not
only gentle and safe for compromised skin, but also accelerate the
visible improvement in the appearance of side effects associated with
"Obagi has significant expertise and a proven track record of marketing
physician-dispensed products. We believe this relationship will
accelerate our penetration in the marketplace and bring ReGenica Facial
Rejuvenation Complex to more physicians in need of a cutting edge
post-procedure solution and are excited to have a company as successful
as Obagi as our partner," commented Nicholas Teti, Chairman and Chief
Executive Officer of Suneva Medical.
The ReGenica Facial Rejuvenation Complex is available for purchase in
dermatology, plastic surgery and other aesthetic physicians' practices.
To learn more about ReGenica visit www.ReGenica.com or
follow on Facebook:
https://www.facebook.com/ReGenicaSkin and Twitter:
To learn more about Obagi Medical Products, visit http://www.obagi.com/
and follow on Facebook:
About Obagi Medical Products, Inc.
Obagi Medical Products is a specialty pharmaceutical company that
develops, markets and sells, and is a leading provider of, proprietary
topical aesthetic and therapeutic prescription-strength skin care
systems in the physician-dispensed market. Using its Penetrating
Therapeutics™ technologies, Obagi Medical's products are designed to
improve penetration of agents across the skin barrier for common and
visible skin conditions in adult skin including premature aging,
photodamage, hyperpigmentation (irregular or patchy discoloration of the
skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine
lines and wrinkles. Obagi Medical's portfolio, which includes cosmetic,
over-the-counter and prescription products, including 4% hydroquinone,
is sold and promoted only through physician offices and requires
education by a physician on proper use. The history of Obagi's skin care
product introductions is as follows: Obagi Nu-Derm®, Obagi-C®
Rx (a prescription-strength vitamin C and hydroquinone system), Obagi®
Professional-C (a line of highly stable vitamin C serums), Obagi
Condition & Enhance® for use with cosmetic procedures to
enhance patient outcomes and satisfaction, ObagiELASTIderm®
Eye Products and ObagiCLENZIderm® M.D. acne therapeutic
systems, a formulation of ObagiCLENZIderm M.D. Systems for normal to dry
skin, and ObagiELASTIderm Décolletage System, ObagiRosaclear®
System, ObagiELASTILash® Eyelash Solution, Obagi Blue Peel
RADIANCE®, Nu-Derm® Sun Shield SPF 50 and Obagi
Hydrate™. Visit www.obagi.com
Penetrating Therapeutics and Obagi Hydrate are trademarks, and Obagi,
the Obagi logo, Blue Peel RADIANCE, Condition & Enhance, ELASTIderm,
ELASTILash, Nu-Derm, Obagi-C, ObagiCLENZIderm and Rosaclear are
registered trademarks, of Obagi Medical Products, Inc. and/or its
affiliates in the United States and certain other countries.
About Suneva Medical, Inc.
Medical, Inc. is a privately held aesthetics company focused on
developing, manufacturing and commercializing novel, differentiated
products for the dermatology and the plastic and cosmetic surgery
markets. The Company currently markets Artefill®,
Skincare in the U.S. and Bellafill™
in Canada. For more information visit www.sunevamedical.com.
1 Kellar et al. Hypoxic Conditioned Culture Medium
From Fibroblasts Under Embryonic-Like Conditions Supports Healing
Following Post-Laser Resurfacing. Journal of Cosmetic Dermatology, 8;
2 Zimber et al. Human Cell-Conditioned Media Produced
Under Embryonic-Like Conditions Result in Improved Healing Time After
Laser Resurfacing. Aesthetic Plastic Surgery, July 2011.
ReGenica® is a trademark of Histogen, Inc.,
exclusively licensed to Suneva Medical, Inc.
[ Back To NFVZone's Homepage ]